Creative Planning
VNDA icon

Creative Planning’s Vanda Pharmaceuticals VNDA Stock Holding History

Creative Planning’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$445K Buy
72,657
+39,296
+118% +$257K ﹤0.01% 3280
2026
Q1 		$231K Buy
+33,361
New +$257K ﹤0.01% 3633
2017
Q3 		– Sell
-1,700
Closed -$28K – 3665
2017
Q2 		$28K Buy
1,700
+500
+42% +$7.21K ﹤0.01% 2942
2017
Q1 		$17K Buy
1,200
+1,100
+1,100% +$15.7K ﹤0.01% 3239
2016
Q4 		$2K Hold
100
– – ﹤0.01% 4313
2016
Q3 		$2K Hold
100
– – ﹤0.01% 4261
2016
Q2 		$1K Sell
100
-100
-50% -$968 ﹤0.01% 4222
2016
Q1 		$2K Sell
200
-3,400
-94% -$27.9K ﹤0.01% 3997
2015
Q4 		$34K Buy
3,600
+3,500
+3,500% +$34.9K ﹤0.01% 2431
2015
Q3 		$1K Buy
+100
New +$1.22K ﹤0.01% 4159

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Creative Planning's VNDA Position: Q2 2026 in Review

Creative Planning increased its Vanda Pharmaceuticals (VNDA) stake by 118% in Q2 2026, buying an estimated $257K and bringing the position to 72,657 shares worth $445K. The position accounts for ﹤0.01% of the portfolio, ranked #3280.

Creative Planning first reported a position in VNDA in Q3 2015 and has held it in 10 quarters since. 172 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

  • Creative Planning held 72,657 shares of Vanda Pharmaceuticals worth $445K as of Q2 2026.
  • Creative Planning bought 39,296 Vanda Pharmaceuticals shares in Q2 2026, an estimated $257K.
  • Vanda Pharmaceuticals made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #3280 holding.
  • Creative Planning first reported a position in Vanda Pharmaceuticals in Q3 2015 and has held it in 10 quarters since.
  • 172 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.